title: Prediction of bone loss in patients with primary hyperparathyroidism using quantitative bone SPECT.
abstract: Bone loss is a major complication of primary hyperparathyroidism (PHPT), and it has significant implications in the treatment of this disease. Bone turnover was measured in patients with PHPT, using quantitative bone SPECT (QBS), to determine if the rate of bone loss could be predicted before a significant decrease in bone mass occurs.
  
  
  METHODS
  Forty-six patients were included in the study. QBS and bone mineral density (BMD) of the lumbar spine (LS) and femoral neck (FN) were done at baseline. The percent deviation of QBS in patients with PHPT from the values in normal matched controls was calculated. BMD was measured again after a mean of 17.5 mo in 38 patients, and in 29 patients a repeat BMD study was done after a mean of 41.4 mo. The change in BMD in patients with high and normal QBS values was compared using the nonparametric Mann-Whitney test. Regression analysis tested the correlation between baseline QBS values and BMD changes over time.
  
  
  RESULTS
  For the FN, there was a statistically significant difference in the BMD change between patients with high and normal QBS values for short-term follow-up (-2.82%+/-4.80% versus 1.45%+/-4.67%, p < 0.05) and for long-term follow-up (-3.53%+/-5.34% versus 0.92%+/-2.40, p < 0.02). There was a negative correlation in the FN, r=-0.48 between QBS values and the percentage of change in BMD. There was no significant difference between the percentage of change in BMD in the LS in patients with high and normal QBS values for either short- or long-term follow-up.
  
  
  CONCLUSIONS
  The results of this study show that QBS can predict bone loss in the FN in patients with PHPT. QBS can thus indicate the need for surgery at an early stage of the disease to prevent bone loss.
authors.affiliation: Department of Nuclear Medicine, Rambam Medical Center and Carmel Lady Davis Hospital, Haifa, Israel.
authors.forename: O
authors.initials: O
authors.lastname: Israel
authors.forename: S
authors.initials: S
authors.lastname: Gips
authors.forename: R
authors.initials: R
authors.lastname: Lubushitzky
authors.forename: L
authors.initials: L
authors.lastname: Bettman
authors.forename: G
authors.initials: G
authors.lastname: Iosilevsky
authors.forename: R
authors.initials: R
authors.lastname: Hardoff
authors.forename: E
authors.initials: E
authors.lastname: Baron
authors.forename: D
authors.initials: D
authors.lastname: Daoud
authors.forename: G M
authors.initials: GM
authors.lastname: Kolodny
authors.forename: D
authors.initials: D
authors.lastname: Front
mesh_terms: D000328:Adult; D000368:Aged; D015519:Bone Density; D001862:Bone Resorption / Q000000981:diagnostic imaging* / Q000209:etiology; D005260:Female; D005272:Femur Neck / Q000000981:diagnostic imaging; D006801:Humans; D006961:Hyperparathyroidism / Q000150:complications / Q000000981:diagnostic imaging*; D008137:Longitudinal Studies; D008159:Lumbar Vertebrae / Q000000981:diagnostic imaging; D008297:Male; D008875:Middle Aged; D019275:Radiopharmaceuticals; D013669:Technetium Tc 99m Medronate; D015899:Tomography, Emission-Computed, Single-Photon
chemical_list: D019275:Radiopharmaceuticals; D013669:Technetium Tc 99m Medronate